RE
ADPT icon

RBC Europe’s Adaptive Biotechnologies ADPT Stock Holding History

RBC Europe’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67
Closed -$2.28K – 636
2021
Q3 		$2.28K Hold
67
– – ﹤0.01% 1116
2021
Q2 		$2.74K Sell
67
-450
-87% -$17.5K ﹤0.01% 1096
2021
Q1 		$20.8K Buy
517
+67
+15% +$3.63K ﹤0.01% 751
2020
Q4 		$26.6K Buy
+450
New +$23.2K ﹤0.01% 646

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

RBC Europe's ADPT Position: Q4 2021 in Review

RBC Europe sold out of Adaptive Biotechnologies (ADPT) in Q4 2021, closing a stake of 67 shares — an estimated $2.28K sold.

RBC Europe first reported a position in ADPT in Q4 2020 and held it in 4 quarters. The position peaked at $26.6K in Q4 2020. 214 funds tracked by Wall St. Rank hold ADPT as of Q4 2021.

  • RBC Europe reported no remaining Adaptive Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 67 Adaptive Biotechnologies shares in Q4 2021, an estimated $2.28K.
  • RBC Europe first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 4 quarters.
  • RBC Europe's Adaptive Biotechnologies position peaked at $26.6K in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.